Business UpdateMay 13, 2026, 04:08 PM
Personalis NeXT Personal Test Gets Expanded Medicare Coverage
AI Summary
Personalis, Inc. announced that the Centers for Medicare & Medicaid Services (CMS) Molecular Diagnostics Program has expanded Medicare coverage for its ultrasensitive NeXT Personal® test. This expansion now includes immunotherapy monitoring for patients diagnosed with late-stage solid tumors. The new coverage became effective on May 12, 2026, significantly broadening the test's utility and market access.
Key Highlights
- CMS expanded Medicare coverage for Personalis' ultrasensitive NeXT Personal® test.
- Expanded coverage includes immunotherapy monitoring.
- The test is for patients with late-stage solid tumors.
- The expanded coverage became effective on May 12, 2026.